|
1
|
Rabinowicz R, Barchana M, Liphshiz I,
Futerman B, Linn S and Weyl-Ben-Arush M: Cancer incidence and
survival among children and adolescents in Israel during the years
1998 to 2007. J Pediatr Hematol Oncol. 34:421–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferguson WS and Goorin AM: Current
treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sarkar A and Hochedlinger K: The sox
family of transcription factors: Versatile regulators of stem and
progenitor cell fate. Cell Stem Cell. 12:15–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alatzoglou KS, Azriyanti A, Rogers N, Ryan
F, Curry N, Noakes C, Bignell P, Hall GW, Littooij AS, Saunders D,
et al: SOX3 deletion in mouse and human is associated with
persistence of the craniopharyngeal canal. J Clin Endocrinol Metab.
99:E2702–E2708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Archer TC, Jin J and Casey ES: Interaction
of Sox1, Sox2, Sox3 and Oct4 during primary neurogenesis. Dev Biol.
350:429–440. 2011. View Article : Google Scholar :
|
|
7
|
Acloque H, Ocaña OH, Matheu A, Rizzoti K,
Wise C, Lovell-Badge R and Nieto MA: Reciprocal repression between
Sox3 and snail transcription factors defines embryonic territories
at gastrulation. Dev Cell. 21:546–558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xia Y, Papalopulu N, Vogt PK and Li J: The
oncogenic potential of the high mobility group box protein Sox3.
Cancer Res. 60:6303–6306. 2000.PubMed/NCBI
|
|
9
|
Yang J, Yuan D, Li J, Zheng S and Wang B:
miR-186 downregulates protein phosphatase PPM1B in bladder cancer
and mediates G1-S phase transition. Tumour Biol. 37:4331–4341.
2016. View Article : Google Scholar
|
|
10
|
Cai QY, Liang GY, Zheng YF, Tan QY, Wang
RW and Li K: Sox3 silencing inhibits metastasis and growth of
esophageal squamous cell carcinoma cell via Downregulating GSK-3β.
Int J Clin Exp Pathol. 9:2939–2949. 2016.
|
|
11
|
Basu-Roy U, Seo E, Ramanathapuram L, Rapp
TB, Perry JA, Orkin SH, Mansukhani A and Basilico C: Sox2 maintains
self renewal of tumor-initiating cells in osteosarcomas. Oncogene.
31:2270–2282. 2012. View Article : Google Scholar
|
|
12
|
Yang C, Hou C, Zhang H, Wang D, Ma Y,
Zhang Y, Xu X, Bi Z and Geng S: miR-126 functions as a tumor
suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci.
15:423–437. 2013. View Article : Google Scholar
|
|
13
|
Zhu H, Tang J, Tang M and Cai H:
Upregulation of SOX9 in osteosarcoma and its association with tumor
progression and patients' prognosis. Diagn Pathol. 8:1832013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Z, Liu J, Wang J and Zhang F: SOX18
knockdown suppresses the proliferation and metastasis, and induces
the apoptosis of osteosarcoma cells. Mol Med Rep. 13:497–504. 2016.
View Article : Google Scholar
|
|
15
|
Oltval ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar
|
|
16
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li K, Wang RW, Jiang YG, Zou YB and Guo W:
Overexpression of Sox3 is associated with diminished prognosis in
esophageal squamous cell carcinoma. Ann Surg Oncol. 20(Suppl 3):
S459–S466. 2013. View Article : Google Scholar
|
|
19
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Otsubo T, Akiyama Y, Yanagihara K and
Yuasa Y: SOX2 is frequently downregulated in gastric cancers and
inhibits cell growth through cell-cycle arrest and apoptosis. Br J
Cancer. 98:824–831. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Huang S, Dong W, Li L, Feng Y,
Pan L, Han Z, Wang X, Ren G, Su D, et al: SOX7, downregulated in
colorectal cancer, induces apoptosis and inhibits proliferation of
colorectal cancer cells. Cancer Lett. 277:29–37. 2009. View Article : Google Scholar
|
|
22
|
Ferletta M, Caglayan D, Mokvist L, Jiang
Y, Kastemar M, Uhrbom L and Westermark B: Forced expression of
Sox21 inhibits Sox2 and induces apoptosis in human glioma cells.
Int J Cancer. 129:45–60. 2011. View Article : Google Scholar
|
|
23
|
Lee RJ, Albanese C, Stenger RJ, Watanabe
G, Inghirami G, Haines GK III, Webster M, Muller WJ, Brugge JS,
Davis RJ, et al: pp60(v-src) induction of cyclin D1 requires
collaborative interactions between the extracellular
signal-regulated kinase, p38, and Jun kinase pathways. A role for
cAMP response element-binding protein and activating transcription
factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol
Chem. 274:7341–7350. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shtutman M, Zhurinsky J, Simcha I,
Albanese C, D'Amico M, Pestell R and Ben-Ze'ev A: The cyclin D1
gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad
Sci USA. 96:5522–5527. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vijayakumar S, Liu G, Rus IA, Yao S, Chen
Y, Akiri G, Grumolato L and Aaronson SA: High-frequency canonical
Wnt activation in multiple sarcoma subtypes drives proliferation
through a TCF/β-catenin target gene, CDC25A. Cancer Cell.
19:601–612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kormish JD, Sinner D and Zorn AM:
Interactions between SOX factors and Wnt/β-catenin signaling in
development and disease. Dev Dyn. 239:56–68. 2010.
|
|
27
|
Zorn AM, Barish GD, Williams BO, Lavender
P, Klymkowsky MW and Varmus HE: Regulation of Wnt signaling by Sox
proteins: XSox17 alpha/beta and XSox3 physically interact with
beta-catenin. Mol Cell. 4:487–498. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Xu Y, Chen Y, Chen S, Jia X, Sun T,
Liu Y, Li X, Xiang R and Li N: SOX2 promotes tumor metastasis by
stimulating epithelial-to-mesenchymal transition via regulation of
WNT/β-catenin signal network. Cancer Lett. 336:379–389. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang N, Hui L, Wang Y, Yang H and Jiang X:
SOX2 promotes the migration and invasion of laryngeal cancer cells
by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep.
31:2651–2659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang N, Hui L, Wang Y, Yang H and Jiang X:
Overexpression of SOX2 promotes migration, invasion, and
epithelial-mesenchymal transition through the Wnt/β-catenin pathway
in laryngeal cancer Hep-2 cells. Tumour Biol. 35:7965–7973. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jafarnejad SM, Wani AA, Martinka M and Li
G: Prognostic significance of Sox4 expression in human cutaneous
melanoma and its role in cell migration and invasion. Am J Pathol.
177:2741–2752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parvani JG and Schiemann WP: Sox4, EMT
programs, and the metastatic progression of breast cancers:
Mastering the masters of EMT. Breast Cancer Res. 15:R722013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guan Z, Zhang J, Wang J, Wang H, Zheng F,
Peng J, Xu Y, Yan M, Liu B, Cui B, et al: SOX1 Downregulates
β-catenin and reverses malignant phenotype in nasopharyngeal
carcinoma. Mol Cancer. 13:2572014. View Article : Google Scholar
|
